No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home REAL ESTATE

London-based LabGenius raises over €40.1 million to further develop its ML-driven antibody discovery platform

EU Startupsby EU Startups
May 21, 2024
Reading Time: 3 mins read
in REAL ESTATE, UK&IRELAND, VENTURE CAPITAL
Share on FacebookShare on Twitter

London-based LabGenius, a drug discovery company pioneering the use of machine learning for the discovery of novel therapeutic antibodies, today announced that it has closed a Series B financing round of over €40.1 million. The investment brings LabGenius’ total funding to date to more than €67.8 million.

The round was led by new investor M Ventures (the strategic, corporate venture capital arm of science and technology company Merck), with participation from additional new investors Octopus Ventures and LG Corp, together with existing investors including Atomico, Kindred Capital, Lux Capital and Obvious Ventures.

LabGenius will use the capital raised to expand the scope of its ML-driven discovery platform and progress a wholly-owned pipeline of multispecific antibodies towards the clinic. Building on the success of a recent research collaboration with Sanofi, the extended platform capability will facilitate broader strategic partnerships across multiple therapeutic modalities.

LabGenius’ unique discovery capability is powered by EVA™: a smart robotic platform capable of designing, conducting and, critically, learning from its own experiments. This highly automated closed-loop discovery engine enables the rapid identification of high-performing antibodies with non-intuitive designs.

For its wholly-owned pipeline, the company is using its platform to address the challenge of on-target, off-tumour toxicity. Therapeutic antibodies target diseased cells by binding to surface markers that are present at higher-than-normal levels. In the case of solid tumours, a challenge with this approach is that sub-populations of healthy cells often express the same surface markers. If a therapeutic antibody fails to differentiate between healthy and diseased cells expressing the same surface markers, the on-target off-tumour killing will occur. Toxicity via this mechanism is a significant issue for many therapeutics in development.

Optimising antibodies for tumour selectivity in combination with other key factors like potency, efficacy and developability is a considerable challenge. With conventional methods, antibodies are sequentially optimised for different properties of interest. This process is inherently inefficient as improving one property in isolation can result in a performance loss across other key properties. LabGenius’ pioneering technology platform uses an active learning method called Multi-Objective Bayesian Optimisation (MOBO) to enable the efficient co-optimisation of antibodies across multiple important properties. In addition to being more efficient than conventional methods, the LabGenius process is also designed to be free from human bias and yields high-performing antibodies with non-intuitive designs.

Dr. Oliver Hardick, of M Ventures, said: “LabGenius’ differentiated ML-driven platform enables the rapid co-optimisation of complex multispecific antibodies across both disease-relevant cell-based assays and key developability assays. The LabGenius approach has the potential to address many of the fundamental challenges faced by antibody engineers. We are excited to lead this financing alongside our co-investors and partner with LabGenius’ exceptional team as they scale their platform and progress their pipeline towards the clinic.”

Dr. James Field, Chief Executive Officer of LabGenius, commented: “Being able to engineer complex multispecific antibodies has immense potential value. Over several years, the LabGenius team has pioneered the development of EVA™- a discovery platform that’s capable of systematically identifying novel high-performing multispecific antibodies with non-intuitive designs. I am inspired by the relentless drive that our team has shown in getting us to this important milestone and look forward to working with our investors as we accelerate the development of both our platform and pipeline.”

Dr. Edwin Moses, Chairman of LabGenius’ Board and former CEO of Ablynx, added: “Closing a round of this size and with such high-quality investors is a testament both to the power and potential of the LabGenius platform and also the quality and dedication of the LabGenius team. We look forward to using our unique and powerful platform to develop new medicines to meet high unmet medical needs and in doing so, reward all our stakeholders for their extraordinary support.”

Read the orginal article: https://www.eu-startups.com/2024/05/london-based-labgenius-raises-over-e40-1-million-to-further-develop-its-ml-driven-antibody-discovery-platform/

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

DACH

Berlin-based VOYA Games Raises €4.4 million to launch debut title Craft World – a dinosaur apocalypse crafting game

May 23, 2025
UK&IRELAND

Microsoft-backed AI startup Builder.ai enters insolvency proceedings

May 23, 2025
DACH

H3C NAVIGATE Global Summit 2025 Kicks Off in Berlin

May 23, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Venture capital investments top €1.3bn in 208 rounds as of Sep30  in Italy. They were €1.5 in all 2023. The new BeBeez Report

Venture capital investments top €1.3bn in 208 rounds as of Sep30 in Italy. They were €1.5 in all 2023. The new BeBeez Report

October 28, 2024
Next Post

Guilhèm Becvort joins White & Case as a partner in Luxembourg

Danish biotech startup raises €4.9M to scale sustainable alternative to petrochemicals

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart